Allon Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing and marketing central nervous system therapies. Its preclinical drug candidate comprises AL-309 for the treatment of peripheral neuropathy. The company was formerly known as Neuro Discovery Inc. and changed its name to Allon Therapeutics Inc. in September 2004. Allon Therapeutics Inc. was incorporated in 1994 and is headquartered in Vancouver, Canada.